

CENTRAL OBESITY IS AN INDEPENDENT RISK FACTOR FOR ALBUMINURIA IN NONDIABETIC INDIAN SUBJECTS

Premshanker Singh^{*1}, Ritu Karoli² and Shobhit Shakya³

¹FMR Prof and Head Medicine, Dr RML Institute of Medical Sciences, Lucknow, India-226010.

²Addl Prof Medicine, Dr RML Institute of Medical Sciences, Lucknow, India-226010.

³Assoc Prof Medicine Dr RML Institute of Medical Sciences, Lucknow, India-226010.

Received date: 22 December 2021

Revised date: 12 January 2022

Accepted date: 02 February 2022

*Corresponding Author: Premshanker Singh

FMR Prof and Head Medicine, Dr RML Institute of Medical Sciences, Lucknow, India-226010.

ABSTRACT

Indian have a high prevalence of central obesity. When the diagnosis of diabetes is made, they have a very high risk of developing renal failure. In the current study, we explored the hypothesis that central obesity is associated with the development of renal injury, before the manifestation of diabetes. We invited first-degree nondiabetic relatives of Indian type- 2 diabetic patients for investigation of microalbuminuria and diabetes. Subjects who used antihypertensive or antidiabetic medication were excluded. We performed a glucose tolerance test according to the classic World Health Organization criteria. A total of 410 subjects were normoglycemic; we excluded 50 subjects because of impaired glucose tolerance, and 60 subjects were excluded because of de novo diabetes. Central obesity was measured by waist-to-hip ratio (WHR). Albuminuria was measured as albumin-to-creatinine ratio (ACR) in the early-morning urine. Central obesity was independently related with albuminuria in the 410 normoglycemic subjects. We found no relation of fasting blood glucose or systolic blood pressure with albuminuria. Multivariate analysis for the presence of increased albuminuria (median ACR >0.31 mg/mmol) showed a relative risk of 4.1 for the highest versus the lowest tertile of WHR ($P = 0.002$). Central obesity is an early and independent risk factor for increased albuminuria in normoglycemic Indian subjects. This could explain the high incidence of diabetic renal disease in Indian population, probably by the mechanism of insulin resistance and endothelial dysfunction in the pre-diabetic state.

INTRODUCTION

People of South Asian background (from India, Pakistan, Bangladesh, and Sri Lanka) have a three times higher risk of developing diabetic nephropathy.^[1] and an almost 40-fold increased risk for end-stage diabetic nephropathy when compared with Caucasians.^[2] The higher prevalence of diabetes only partially explains this high risk.^[3,4,5,6] Also, classical risk factors for nephropathy, like hypertension, smoking, BMI, age, A1C or family history did not explain these renal complications in South Asians.^[1,7] A population survey in the U.K. showed more microalbuminuria in South Asians when compared with Europeans.^[8,9,10] After adjustment for age, hypertension, and diabetes, urinary albumin excretion was still higher in South Asians than Europeans. Therefore, the risk to develop renal injury appears to occur earlier in the course of the disease.

Central obesity reflected by a high waist-to-hip ratio (WHR) has only recently received more attention as a

potential risk factor for renal disease in nondiabetic subjects.^[9,10] The pathogenesis is unclear and could be mediated primarily by adipogenic inflammation and endothelial dysfunction giving microalbuminuria or secondarily by hypertension and hyperglycemia, which accompany central obesity.

Central obesity is known to be more common in South Asians compared with Caucasians.^[11,12] Moreover, at the same level of WHR, South Asians seem to have increased abdominal visceral fat and greater insulin resistance compared with Caucasians.^[12,13] It is not known whether this central obesity could explain the high risk for diabetic nephropathy in South Asian patients. Especially, we wanted to know whether central obesity is associated with the presence of renal injury (albuminuria) at a stage before the diabetes is diagnosed, independent of other risk factors as blood pressure and fasting blood glucose.

MATERIAL AND METHOD

The study was setup to detect a genetic susceptibility for nephropathy within the Indian population by assessing whether familial clustering of nephropathy occurs in families of Indian type 2 diabetic patients with end-stage renal failure. In the former published study, nephropathy prevalence was studied between two groups of first-degree relatives of Indian patients with type 2 diabetes. The first group (case relatives) consisted of 169 relatives of patients with end-stage diabetic nephropathy. The second group (control relatives) consisted of 161 relatives of diabetic patients who had no nephropathy. Researchers found more nephropathy in relatives of Indian type 2 diabetic patients with end-stage diabetic nephropathy in comparison with control relatives. Diabetes was distributed equally in both family groups.

In the current study, we had 330 first-degree family members. To prevent confounding by the antihypertensive or antidiabetes medication on the outcome of albuminuria, we excluded 70 patients. The remaining 260 relatives had a glucose tolerance test (GTT), using the classic World Health Organization criteria¹⁵. A fasting blood glucose >7.8 mmol/l or a 2-h GTT value >11.1 mmol/l was classified as de novo diabetes. If the fasting blood glucose was <7.8 mmol/l and 2-h GTT value was between 7.8 and 11.1 mmol/l, they were classified as impaired glucose tolerance. A 2-h GTT value <7.8 mmol/l was classified as normoglycemic. After testing, 205 subjects were normoglycemic and eligible for our study. We excluded 25 subjects with impaired glucose tolerance, and 30 subjects with de novo diabetes from further analysis.

All first-degree relatives (father, mother, siblings, and children) of the study population diabetic patients were invited as part of a family investigation for diabetes and renal disease. We invited the relatives at random during the investigation period. Relatives who were pregnant were invited later on, 3 months after they gave birth. Subjects aged <16 years were not included. We tried to avoid appointments during the menstrual period of women. The study protocol was approved by the institutional medical ethics committee.

The family relatives came during the morning hours, after fasting for at least 8 h. Fasting venous blood samples were drawn. An oral GTT was done with 75 g glucose, and the fasting glucose and 2-h glucose were measured. The relatives brought an early morning urine sample for quantitative measurements of albuminuria. They stayed in a quiet room, and the blood pressure was measured three times after a 5-min rest in the sitting position using an OMRON 705CP automatic oscillometric blood pressure device. The weight and height were recorded in underwear, just as the circumference measurements of the waist and hip. A questionnaire was used to obtain data on age, sex, diabetes, hypertension, smoking, and medication.

Urinary albumin and protein were measured by immunoturbidimetric assay on a Hitachi 911, as was the HDL cholesterol in serum. Glucose, creatinine, cholesterol, and triglycerides were measured on a Hitachi 747 (Hitachi, Tokyo, Japan). A1C was measured using the high-performance liquid chromatography method with a Variant Analyzer (Biorad, Hercules, CA). Variance coefficient was 1.5% at different levels. The reference values for HbA1C were between 4.3 and 6.3%. C-reactive protein (CRP) was measured on a fully automated P 800 analyzer (Roche/Hitachi, Tokyo, Japan) with an immunoturbidimetric assay. The interassay variance coefficient was <2.5% at different levels. Albuminuria was measured in relation to creatinine and expressed as the albumin-to-creatinine ratio (ACR) (in mg/mmol). The renal function was estimated using the adjusted four-variable Modification of Diet in Renal Disease formula.^{16]}

Statistical analysis

The relation of albuminuria with tertiles WHR, blood glucose, and systolic blood pressure was studied in the nondiabetic normoglycemic subjects ($n = 205$). Continuous variables were expressed as means \pm SD, unless otherwise specified. Student's t test was used for continuous variables and the χ^2 test for categorical variables to compare differences between albuminuria groups. The tertiles of WHR were stratified for sex to abolish sex-specific differences in WHR. For comparing differences in median ACR and CRP between the lowest versus the highest tertile of WHR, the Mann-Whitney test was used. Multivariate logistic regression analysis was performed for increased albuminuria as dependent variable. We defined "increased" albuminuria as ACR higher than the median value of the analyzed study group (>0.31 mg/mmol). We used systolic blood pressure, 2-h blood glucose, BMI, and age as continuous variables and used smoking, sex, and tertiles of WHR as categorical variables. Current smokers and subjects who stopped smoking <5 years ago were classified as smokers; all others were classified as nonsmokers.

RESULT

The characteristics of the 205 normoglycemic subjects are shown in relation to low or increased ACR in Table-1. The mean ACR was 0.17 mg/mmol in the low albuminuria versus 0.96 in the increased albuminuria group. The subjects had a mean age of ~37 years, and 44% was male. Subjects with increased albuminuria had a slightly higher WHR and blood pressure. The mean BMI and CRP were lower in the increased albuminuria group. There were no differences in age, sex, smoking, and familial renal disease between the groups. Renal function, measured as Modification of Diet in Renal Disease formula, was slightly higher in the increased albuminuria group.

The median ACR in the urine in relation to tertiles of central obesity (WHR) was measured. The median ACR rose simultaneously with increasing tertiles of WHR.

The difference in median ACR between the lowest versus the highest tertile WHR was 0.16 mg/mmol ($P = 0.015$). The median CRP also correlated with the increase of the WHR tertiles. The difference in CRP between the lowest versus the highest tertile was 2 mg/l ($P = 0.02$).

Univariate and multivariate analysis

The results of the univariate analysis for having an increased albuminuria (ACR >0.31 mg/mmol) are shown in **Table 1** (univariate odds ratio). There was a significant relation between urinary albumin excretion >0.31 mg/mmol with WHR. No relation could be found for age, BMI, weight, fasting and 2-h blood glucose, triglycerides, smoking, blood pressure, CRP, and family history in the univariate analysis.

After adjustment for only age and sex, we found a twice-higher risk for increased albuminuria (ACR >0.31 mg/mmol) for the higher versus the lower tertile of WHR (odds ratio 2.2 [95% CI 1.06–4.4]; $P = 0.03$). Separate multivariate analysis stratified for sex or BMI subsets revealed no different conclusions. There was no relation of sex and BMI with increased albuminuria. The results of the adjusted multivariate analysis for sex, age, smoking, systolic blood pressure, CRP, 2-h blood glucose, and BMI are shown in **Table 2** (multivariate odds ratio). After multivariate adjustment, the odds ratio for increased albuminuria went up to 4.1 for the highest WHR tertile ($P = 0.002$).

Table-1: Basic characteristics of 205 normoglycemic Indian.

	Total	ACR			P value
		≤0.31	>0.31		
<i>n</i>	205	105	100		
WHR	0.90 ± 0.08	0.89 ± 0.08	0.91 ± 0.08	0.15	
ACR (mg/mmol)	0.55 ± 1.36	0.17 ± 0.09	0.96 ± 1.9	<0.001	
Age (years)	37.3 ± 9.4	36.9 ± 9.4	37.0 ± 9.5	0.92	
Male sex (%)	43.9	44.8	43.0	0.80	
BMI (kg/m ²)	25.4 ± 4.2	25.7 ± 4.3	25.1 ± 4.1	0.32	
Fasting glucose	5.1 ± 0.54	5.1 ± 0.55	5.1 ± 0.54	0.46	
2-h blood glucose	5.4 ± 1.21	5.4 ± 1.18	5.4 ± 1.25	0.97	
Total cholesterol	5.17 ± 0.99	5.2 ± 0.97	5.1 ± 1.01	0.45	
HDL cholesterol	1.3 ± 0.36	1.3 ± 0.38	1.3 ± 0.35	0.69	
Triglycerides	1.3 ± 0.70	1.2 ± 0.63	1.4 ± 0.77	0.26	
CRP	4.2 ± 6.1	4.7 ± 6.1	3.6 ± 6.0	0.19	
Smoking (%)	34.8	35.2	34.3	0.89	
Systolic blood pressure (mmHg)	120 ± 15.6	119 ± 12.6	120 ± 18.2	0.51	
Diastolic blood pressure (mmHg)	76 ± 10.0	75 ± 8.9	77 ± 11.0	0.10	
MDRD clearance (ml/min per 1.73 m ²)	85 ± 13.0	83 ± 13.1	87 ± 12.6	0.027	
Family history of renal failure (%)	53.7	53.3	54.0	0.92	

Data are means ± SD, unless otherwise indicated. The subjects represented, as total group, low albuminuria (ACR ≤0.31 mg/mmol) and increased albuminuria (ACR

>0.31 mg/mmol). MDRD, Modification of Diet in Renal Disease.

Table 2: Univariate and multivariate analysis for increased albuminuria (ACR >0.31 mg/mmol) as a dependent variable.

	Odds ratio of increased albuminuria (95% CI)			
	Univariate odds ratio	P value	Multivariate odds ratio*	P value
WHR tertiles				
Low	1.0 (ref.)	—	1.0 (ref.)	
Middle	1.5 (0.75–2.9)	0.26	2.2 (1.0–4.7)	0.05
High	2.0 (1.03–4.0)	0.04	4.1 (1.6–10.0)	0.002
Female sex	1.1 (0.62–1.9)	0.80	1.5 (0.80–3.0)	0.20
Age	1.0 (0.97–1.03)	0.92	0.97 (0.94–1.01)	0.15
Smoking	0.96 (0.54–1.71)	0.89	1.04 (0.55–1.96)	0.90
BMI	0.97 (0.91–1.03)	0.32	0.91 (0.83–0.99)	0.03
Systolic blood pressure (per 10 mmHg)	1.06 (0.89–1.27)	0.51	1.17 (0.93–1.47)	0.17
CRP	0.97 (0.92–1.02)	0.19	0.96 (0.91–1.01)	0.16
2-h glucose	1.0 (0.8–1.26)	0.97	0.99 (0.77–1.28)	0.94

Adjusted for WHR, sex, age, smoking, BMI, blood pressure, CRP, and glucose.

DISCUSSION

The current study demonstrates that central obesity is the single most important risk factor for increased urinary albumin excretion in nondiabetic Indian subjects. This relationship was even strengthened after correction for BMI, underscoring the critical role of visceral fat in this relationship. With the increasing central obesity, other components of the metabolic syndrome, such as higher blood glucose, CRP, triglycerides, and a higher blood pressure, emerged. However, none of these factors could independently predict the occurrence of increased urinary albumin excretion. The ACRs in our study are below the conventional definitions of microalbuminuria. Recent studies.^[17,18,19,20] indicate that comparable levels of albuminuria well below the traditional threshold are a continuous risk factor for cardiovascular morbidity and mortality. Due to the lack of a threshold value for increased cardiovascular risk, we defined increased albuminuria as an ACR higher than the median value of the analyzed study group (>0.31 mg/mmol). These findings suggest that the observed increase of urinary albumin excretion associated with an increased WHR is an important predictor of cardiovascular morbidity in this high-risk Indian population.

In the current study, we used first-degree relatives of Indian type 2 diabetic patients. Therefore, the current results most likely can be related to the Indian ethnicity. It is of interest that such a specific independent relation between visceral obesity and increased albumin excretion has not been described in South Asians.^[14,15] Several studies in Caucasians.^[10,21,22,23,24,25,26] found a relation between metabolic syndrome, obesity, microalbuminuria and renal insufficiency.^[27,28] Studies in non-Caucasian populations revealed conflicting results. For example, in Hispanics, no relationship was found.^[29] while in Korean subjects a relationship between central obesity and microalbuminuria could be found.^[30] We found a clear independent relation with central obesity in nondiabetic Indian, emphasizing this mechanism in this population. The Study of Health Assessment in Ethnic Groups showed higher fasting blood glucose, cholesterol, and systolic blood pressure in Indian in comparison with Europeans for the same BMI or WHR. Even in the normal range, the metabolic markers were still higher. The reference value of WHR and BMI in Indian has to be adjusted downwards and further studies are warranted to address this issue.^[30,31]

These findings have major implications for the public health in this ethnic group. Indian are very prone to obesity and type 2 diabetes.^[12,13] This susceptibility for central obesity and insulin resistance could explain the higher rates of end-stage diabetic nephropathy in migrant Indian.^[2] Apparently, by the time the diagnosis of type 2 diabetes is made, the subjects already may have developed renal injury.^[7] Our observation may help

explain the high prevalence of diabetic nephropathy in this ethnic group. We cannot deduce the exact mechanisms involved in the link between visceral obesity and the development of nephropathy from our current study. Most likely, this involves a multifactorial complex pathogenesis, including the release of adipokines and proinflammatory cytokines from the visceral adipose tissue, sympathetic activation, and activation of the renin-angiotensin system by adipocytes.^[32,34,35] Irrespective of the pathogenic mechanisms involved, the current study strongly argues for early intervention strategies aimed at reducing visceral obesity in Indian. Lifestyle intervention has proven to be very effective in prevention of the development of type 2 diabetes in other ethnic populations,^[35] and evaluation of such interventions are warranted in this population with regards to their potential prevention of organ damage as well.

CONCLUSION

In present study, relatively young nondiabetic Indian were able to show a clear relation of albuminuria with central obesity, independent of blood glucose, blood pressure and renal function. This could explain the higher rates of microalbuminuria and end-stage diabetic nephropathy in Indian population. Screening for central obesity in Indian with a simple measure tape could identify individuals at risk for developing renal organ damage in the normal glucose range. The urinary median ACR rose simultaneously with increasing tertiles of WHR.

Funding-None.

Conflict of interest-None.

Ethical clearance-Taken from ethical committee.

REFERENCES

1. Chandie Shaw PK, Baboe F, van Es LA, van der Vijver JC, van de Ree MA, de Jonge N, Rabelink TJ: South Asian type 2 diabetic patients have higher incidence and faster progression of renal disease compared with Dutch European diabetic patients. *Diabetes Care*, 2006; 29: 1383–1385.
2. Chandie Shaw PK, Vandenbroucke JP, Tjandra YI, Rosendaal FR, Rosman JB, Geerlings W, de Charro FT, van Es LA: Increased end-stage diabetic nephropathy in Indo-Asian immigrants living in the Netherlands. *Diabetologia*, 2002; 45: 337–341.
3. Mather HM, Keen H: The Southall Diabetes Survey: prevalence of known diabetes in Asians and Europeans. *Br Med J (Clin Res Ed)*, 1985; 291: 1081–1084.
4. Burden AC, McNally PG, Feehally J, Walls J: Increased incidence of end-stage renal failure secondary to diabetes mellitus in Asian ethnic groups in the United Kingdom. *Diabet Med*, 1992; 9: 641–645.
5. Lightstone L, Rees AJ, Tomson C, Walls J, Winearls CG, Feehally J: High incidence of end-stage renal

- disease in Indo-Asians in the UK. *Q*, 1995; 88: 191–195.
6. Middelkoop BJ, Kesarlal-Sadhoeram SM, Ramsaransing GN, Struben HW: Diabetes mellitus among South Asian inhabitants of The Hague: high prevalence and an age-specific socioeconomic gradient. *Int J Epidemiol*, 1999; 28: 1119–1123.
 7. Mather HM, Chaturvedi N, Kehely AM: Comparison of prevalence and risk factors for microalbuminuria in South Asians and Europeans with type 2 diabetes mellitus. *Diabet Med*, 1998; 15: 672–677.
 8. Fischbacher CM, Bhopal R, Rutter MK, Unwin NC, Marshall SM, White M, Alberti KG: Microalbuminuria is more frequent in South Asian than in European origin populations: a comparative study in Newcastle, UK. *Diabet Med*, 2003; 20: 31–36.
 9. Liese AD, Hense HW, Doring A, Stieber J, Keil U: Microalbuminuria, central adiposity and hypertension in the non-diabetic urban population of the MONICA Augsburg survey 1994/95. *J Hum Hypertens*, 2001; 15: 799–804.
 10. Bonnet F, Marre M, Halimi JM, Stengel B, Lange C, Laville M, Tichet J, Balkau B: Waist circumference and the metabolic syndrome predict the development of elevated albuminuria in non-diabetic subjects: the DESIR study. *J Hypertens*, 2006; 24: 1157–1163.
 11. McKeigue PM, Marmot MG, Syndercombe Court YD, Cottier DE, Rahman S, Riemersma RA: Diabetes, hyperinsulinaemia, and coronary risk factors in Bangladeshis in east London. *Br Heart*, 1988; 60: 390–396.
 12. McKeigue PM, Shah B, Marmot MG: Relation of central obesity and insulin resistance with high diabetes prevalence and cardiovascular risk in South Asians. *Lancet*, 1991; 337: 382–386.
 13. Raji A, Seely EW, Arky RA, Simonson DC: Body fat distribution and insulin resistance in healthy Asian Indians and Caucasians. *J Clin Endocrinol Metab*, 2001; 86: 5371.
 14. Chandie Shaw PK, van Es LA, Paul LC, Rosendaal FR, Souverein JH, Vandenbroucke JP: Renal disease in relatives of Indo-Asian type 2 diabetic patients with end-stage diabetic nephropathy. *Diabetologia*, 2003; 46: 618–624.
 15. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care*, 1997; 20: 1183–1197.
 16. Levey A, Greene T, Kusek JW, Beck GJ: A simplified equation to predict glomerular filtration rate from serum creatinine (Abstract). *J Am Soc Nephrol*, 2000; 11: A0828.
 17. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Halle JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. *JAMA*, 2001; 286: 421–426.
 18. Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristianson K, Lederballe-Pedersen O, Nieminen MS, Okin PM, Omvik P, Oparil S, Wedel H, Snapinn SM, Aurup P: Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. *Ann Intern Med*, 2003; 139: 902–906.
 19. Arnlov J, Evans JC, Meigs JB, Wang TJ, Fox CS, Levy D, Benjamin EJ, D'Agostino RB, Vasan RS: Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. *Circulation*, 2005; 112: 969–975.
 20. Ruggenenti P, Remuzzi G: Time to abandon microalbuminuria? *Kidney Int.*, 2006; 70: 1214–1222.
 21. Metcalf P, Baker J, Scott A, Wild C, Scragg R, Dryson E: Albuminuria in people at least 40 years old: effect of obesity, hypertension, and hyperlipidemia. *Clin Chem*, 1992; 38: 1802–1808.
 22. Basdevant A, Cassuto D, Gibault T, Raison J, Guy-Grand B: Microalbuminuria and body fat distribution in obese subjects. *Int J Obes Relat Metab Disord*, 1994; 18: 806–811.
 23. Forsblom CM, Eriksson JG, Ekstrand AV, Teppo AM, Taskinen MR, Groop LC: Insulin resistance and abnormal albumin excretion in non-diabetic first-degree relatives of patients with NIDDM. *Diabetologia*, 1995; 38: 363–369.
 24. Schmidt MI, Watson RL, Duncan BB, Metcalf P, Brancati FL, Sharrett AR, Davis CE, Heiss G: Clustering of dyslipidemia, hyperuricemia, diabetes, and hypertension and its association with fasting insulin and central and overall obesity in a general population: Atherosclerosis Risk in Communities Study Investigators. *Metabolism*, 1996; 45: 699–706.
 25. Valensi P, Assayag M, Busby M, Paries J, Lormeau B, Attali JR: Microalbuminuria in obese patients with or without hypertension. *Int J Obes Relat Metab Disord*, 1999; 20: 57–579.
 26. Jager A, Kostense PJ, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD: Microalbuminuria is strongly associated with NIDDM and hypertension, but not with the insulin resistance syndrome: the Hoorn Study. *Diabetologia*, 1998; 41: 694–700.
 27. Pinto-Sietsma SJ, Navis G, Janssen WM, De Zeeuw D, Gans RO, De Jong PE: A central body fat distribution is related to renal function impairment, even in lean subjects. *Am J Kidney Dis*, 2003; 41: 733–741.
 28. Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, Whelton PK, He J: The metabolic syndrome and chronic kidney disease in U.S. adults. *Ann Intern Med*, 2004; 14: 167–174.

29. Hoffmann IS, Jimenez E, Cubeddu LX: Urinary albumin excretion in lean, overweight and obese glucose tolerant individuals: its relationship with dyslipidaemia, hyperinsulinaemia and blood pressure. *J Hum Hypertens*, 2001; 15: 407–412.
30. Kim YI, Kim CH, Choi CS, Chung YE, Lee MS, Lee SI, Park JY, Hong SK, Lee KU: Microalbuminuria is associated with the insulin resistance syndrome independent of hypertension and type 2 diabetes in the Korean population. *Diabetes Res Clin Pract*, 2001; 52: 145–152.
31. Razak F, Anand S, Vuksan V, Davis B, Jacobs R, Teo KK, Yusuf S: Ethnic differences in the relationships between obesity and glucose-metabolic abnormalities: a cross-sectional population-based study. *Int J Obes (Lond)*, 2005; 29: 656–667.
32. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD: Obesity/insulin resistance is associated with endothelial dysfunction: implications for the syndrome of insulin resistance. *J Clin Invest*, 1996; 97: 2601–2610.
33. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE: Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NFkappaB. *Nat Med*, 2010; 11: 183–190.
34. Yudkin JS, Eringa E, Stehouwer CD: “Vasocrine” signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease. *Lancet*, 2015; 365: 1817–1820.
35. Lindstrom J, Eriksson JG, Valle TT, Aunola S, Cepaitis Z, Hakumaki M, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Mannelin M, Martikkala V, Moltchanov V, Rastas M, Salminen V, Sundvall J, Uusitupa M, Tuomilehto J: Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. *J Am Soc Nephrol*, 2016; 14: S108–S113.